Amyloid β Peptides
Amyloid β (Aβ) peptides are the major component of amyloid plaques found in the brains of Alzheimer's patients. Aβ is formed from the progressive cleavage of amyloid precursor protein (APP) by β- and γ-secretase. Two Aβ peptides are formed from APP degradation.
Amyloid β Peptide Modulators |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 5343 | TPPB |
| APP modulator; also high affinity PKC activator | |
Amyloid β Peptide Inhibitors |
|
| Cat. No. | Product Name / Activity |
| 6363 | Avagacestat |
| Highly potent γ-secretase inhibitor; orally bioavailable | |
| 2870 | BMS 299897 |
| γ-secretase inhibitor; reduces Aβ levels | |
| 4924 | CEP 1347 |
| Neuroprotective; blocks Aβ-induced cortical neuron apoptosis. Also inhibitor of JNK signaling | |
| 2442 | CGP 53353 |
| Inhibitor of de novo Aβ42 assembly | |
| 2634 | DAPT |
| γ-secretase inhibitor; reduces Aβ42 levels | |
| 6779 | Davunetide |
| Highly potent active component of ADNP; prevents amyloid β aggregation; active in vivo | |
| 4524 | EGCG |
| β-secretase inhibitor; inhibits formation of amyloid fibrils | |
| 2627 | L-685,458 |
| Potent and selective γ-secretase inhibitor; inhibits Aβ40 and Aβ42 | |
| 7081 | LY 2886721 Hydrochloride |
| Inhibits Aβ1-40 and 1-42 production in vitro and in vivo; potent and selective β-secretase inhibitor | |
| 4000 | MRK 560 |
| γ-secretase inhibitor; attenuates amyloid plaque deposition | |
| 5751 | PF 3084014 hydrobromide |
| Potent γ-secretase inhibitor | |
| 2408 | Ro 90-7501 |
| Inhibitor of Aβ42 fibril formation | |
| 6762 | Urolithin A |
| Inhibits amyloid-β fibrillation; also PI 3-K/Akt/mTOR signaling inhibitor | |
Other |
|
| Cat. No. | Product Name / Activity |
| 5053 | AC 186 |
| Decreases Aβ levels in combination with ACP-105; ERβ agonist | |
| 1191 | Amyloid β-Peptide (1-40) (human) |
| Amyloid β-protein fragment | |
| 1428 | Amyloid β-Peptide (1-42) (human) |
| Predominant amyloid β-protein fragment | |
| 2425 | Amyloid β-peptide (1-42) (rat) |
| Predominant amyloid β-protein fragment | |
| 1429 | Amyloid β-peptide (25-35) (human) |
| Human amyloid β-protein fragment functionally required for neurotoxicity | |
| 0427 | Bromocriptine mesylate |
| Reduces Aβ levels; D2 and D3 receptor agonist | |
| 3945 | Colivelin |
| Neuroprotective peptide; protects against β-amyloid neurotoxicity | |
| 4803 | CRANAD 2 |
| Near-infrared probe that detects Aβ40 aggregates | |
| 5081 | J 147 |
| Neuroprotective and neurotrophic compound; reduces Aβ40 and Aβ42 levels | |
| 3144 | K 114 |
| Amyloid fibril-specific fluorescent dye | |
| 6517 | Liraglutide |
| Reduces Aβ and soluble amyloid levels in vivo; also highly potent GLP-1 receptor agonist | |
| 4920 | Methoxy-X04 |
| Fluorescent amyloid β detector; brain penetrant | |
| 7712 | Semax |
| Reduces Aβ aggregation and fibrillogenesis; neuroprotective and neurotrophic peptide | |
| 1098 | Tranilast |
| Antiallergic; binds to Aβ40 monomers | |
| 7659 | Verubecestat |
| Potently reduces Aβ formation in vitro and in vivo; BACE1 and BACE2 inhibitor | |
Amyloid β (Aβ) peptides are the major component of amyloid plaques found in the brains of Alzheimer's patients. Aβ is formed from the progressive cleavage of amyloid precursor protein (APP) by β- and γ-secretase. Two Aβ peptides are formed from APP degradation; Aβ40 and Aβ42. Aβ40 is the most abundant form, but Aβ42 is more fibrillogenic, thus is associated with disease states.
Mutations in APP have been linked to early onset Alzheimer's disease, as proteolytic cleavage of the altered protein increases the levels of Aβ42 relative to Aβ40. Furthermore, Aβ proteins have been associated with other diseases including Lewy body dementia, inclusion body myositis and cerebral amyloid angiopathy.
Literature for Amyloid β Peptides
Tocris offers the following scientific literature for Amyloid β Peptides to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Written by Alan Palmer
Our Alzheimer's disease poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease.
Request copyDownload PDF